Monday, 21 Oct 2019

You are here

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

A total of 154 cases were enrolled (77 in each arm) and underwent surgical lavage prior to antibiotic therapy.

The cure rates were 99% in the 2-week arm and 97% in the 4-week arm. There was no difference in the number of adverse events or sequelae between the study arms. Recurrence rates were infrequent and equal between groups (1 vs. 2).

All antibiotics were given intravenously (eg, co-amoxiclav; cefazolin; cefuroxime; cefepime; ertapenem; imipenem; piperacillin/tazobactam; vancomycin; or daptomycin) and refined after culture and sensitivity results.  Patients were switched to oral therapy at the discretion of the treating clinicians.

Of the 154 arthritis cases, 99 were for bacterial infection of the hand and wrist.  Bacteremia was seen in 4% of cases and intraarticular crystals were found in 4% of patients.

In this study, two weeks of targeted antibiotic therapy is not inferior to 4 weeks regarding cure rate, adverse events or sequelae and leads to a significantly shorter hospital stay, at least for hand and wrist arthritis.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Stress and the Risk of Incident Inflammatory Arthritis

A prospective analysis of newly diagnosed, inflammatory arthritis (IA) patients suggests that perceived distress (stress) increases the odds of incident IA.

Juvenile Arthritis at Risk for Coronary Artery Disease

Arthritis Care & Research reports that juvenile arthritis (JA) patients may have a higher risk if coronary artery disease (CAD) in adulthood. 

Data was drawn from the National Health and Nutrition Examination (2007‐2014).  The diagnoses of JA and CAD were self declared by respondents.

Long Delays for Inflammatory Arthritis Patients

The National Rheumatoid Arthritis Society's (NRAS) annual audit has identified significant treatment delays for patients with suspected early inflammatory arthritis could result in unnecessary harm. 

Antibiotics Increase Rheumatoid Risk - Again

Another UK study has suggested that prior use of antibiotics increases the risk of developing rheumatoid arthritis (RA).

Rheumatology has published a 15 year case–control study that compared 8482 newly diagnosed RA patients and 22,661 controls from the UK’s Royal College of General Practitioners Research and Surveillance Centre database (between 2006 and 2018).

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.